Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Moderna to Report Third Quarter Financial Results on Thursday, November 4, 2021


Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 4, 2021 to report its third quarter 2021 financial results, and provide a corporate update.

To access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference ID 9177025. A webcast of the call will also be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.


These press releases may also interest you

at 19:18
ADISA, the nation's largest trade association for the alternative and direct investment space, reacted to the announcement today from the...

at 19:00
Purpose Investments Inc. announced today the updated April 2024 distribution rates, Record and Ex-Distribution dates for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund, and Purpose USD Cash Management Fund (the...

at 19:00
Visionary Holdings Inc. (the "Company") , a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China, today announced on April 22, 2024, the...

at 19:00
The Kansas Proving Grounds at Great Plains Industrial Park, a leading facility for testing and innovation, is proud to announce its partnership with SkyscoutAI Innovations Inc., a pioneer in AI-powered wildfire detection and response using drones and...

at 19:00
UST, a leading digital transformation solutions company, today announced that it has acquired Strativity Group, a boutique strategy consultancy specialising in customer-centric transformations. Strativity is renowned for delivering customer...

at 18:59
The Board of Directors of Canadian Pacific Kansas City Limited (CPKC) today declared a quarterly dividend of $0.19 per share on the outstanding Common Shares. The dividend is payable on July 29, 2024, to holders of record at the close of business...



News published on and distributed by: